Home › Funds › Kohlberg Kravis Roberts & Co. L.P. › BBIO

Kohlberg Kravis Roberts & Co. L.P. position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Kohlberg Kravis Roberts & Co. L.P. reported holding 385,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$581K, representing 0.01% of its reported portfolio and ranking #45 among its reported holdings. Kohlberg Kravis Roberts & Co. L.P. has disclosed BBIO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)385.00K sh
Reported value held$580.77K
Portfolio Weight0.01%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Kohlberg Kravis Roberts & Co. L.P.'s BBIO position evolved

Kohlberg Kravis Roberts & Co. L.P. first disclosed a stake in BBIO in Q3 2023 at 31,060,971 shares (US$819.1M). The position peaked in Q4 2023 at 31,060,971 shares, worth US$1.25B. Across 13 filings, Kohlberg Kravis Roberts & Co. L.P. increased the stake 0 time(s), trimmed it 4 time(s) and left it unchanged 8 time(s). The most recent filing (Q3 2026) shows 385,000 shares valued at US$581K. Notable position changes include a 31% trim in Q2 2025 (shares rose 20% over the following quarter), a 97% trim in Q2 2026 (shares fell 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 31.06M $819.08M New
Q4 2023 31.06M $1.25B Hold
Q1 2024 31.06M $960.41M Hold
Q2 2024 31.06M $786.77M Hold
Q3 2024 25.26M $643.14M Reduce
Q4 2024 25.26M $693.16M Hold
Q1 2025 19.26M $665.85M Reduce
Q2 2025 13.26M $572.61M Reduce
Q3 2025 13.26M $688.77M Hold
Q4 2025 13.26M $1.01B Hold
Q1 2026 13.26M $984.76M Hold
Q2 2026 385.00K $648.53K Reduce
Q3 2026 385.00K $580.77K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 41 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Kohlberg Kravis Roberts & Co. L.P. held BBIO?

Kohlberg Kravis Roberts & Co. L.P. has disclosed BBIO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Kohlberg Kravis Roberts & Co. L.P.'s current position in BBIO?

As of Q3 2026, Kohlberg Kravis Roberts & Co. L.P. holds 385.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $580.77K, representing 0.01% of its reported portfolio and ranking #45.

Has Kohlberg Kravis Roberts & Co. L.P. been buying or selling BBIO?

In the latest 13F filing (Q3 2026), Kohlberg Kravis Roberts & Co. L.P. held unchanged its position in BBIO. The position peaked in Q4 2023 at 31.06M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.